NCT04320888 2026-05-27Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialNational Cancer Institute (NCI)Phase 2 Active not recruiting1 enrolled 3 charts